



Domainex presented at the November 2007 OION meeting. They successfully completed their funding round in April 2008, which included angel investment from one OION investor.

Domainex Ltd is a contract research company that was established in 2001 and operates from Cambridge UK. In May 2007 Domainex merged with NCE Discovery to form a new integrated company with capabilities in biology and chemistry.

Their service division offers technologies designed to clone and express challenging genes to give high-quality recombinant protein displaying functional domains of the target. They also provide computational and medicinal chemistry for the design and synthesis of candidate drugs aimed at our customers' target proteins.

Their drug discovery division seeks to exploit these technologies and expertise against a small portfolio of their own projects. Their internal programmes are exclusively focussed on nucleotide triphosphate binding domains (NTP domains) which are found in several important therapeutic targets.